Vildagliptin

Drug Profile

Vildagliptin

Alternative Names: Equa; Galvus; Jalra; LAF 237; LAF 237A; NVP LAF 237; NVP LAF 237A; Xiliarx

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; University of Sao Paulo
  • Class Antihyperglycaemics; Cycloparaffins; Nitriles; Polycyclic bridged compounds; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Type 1 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Jun 2015 No recent reports on development identified - Phase-II/III for Type-2 diabetes mellitus in Peru and Venezuela (PO)
  • 03 Jun 2015 No recent reports on development identified - Phase-II/III for Type-2 diabetes mellitus (Treatment-naive) in Canada, India, Malaysia, Philippines, Romania and Slovakia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top